Zoom Logo

Drug Re-Purposing Webinar 1 - Shared screen with speaker view
Eric SAMARUT
22:57
Megha, we can’t hear you well…
Tara Barnas
23:10
Megha, we can't hear you very well.
William Szczepaniak
23:16
We can't hear Megha
Kathryn Truscott
24:01
cannot hear megha very well
William Szczepaniak
49:38
Canada Viagra patent - invalidation, is that for failing a Canadian equivalent of "best mode" in USA?
Eric SAMARUT
50:15
In the case of Pregabalin, would a change in dosage or formulation have change the issue with the 2nd medical use patent and the skinny label bypass?
Richard Wilson
50:15
Didn’t the law change allowing publication of data by authors before patent filing?
Paul Stewardson
50:24
Not repurposing exactly - but do you have any comments on the recent rulings on Vascepa?
William Szczepaniak
50:32
Another repurposed strategy to discuss, using the Celgene thalidomide model.
Eric SAMARUT
52:56
Do you confirm that once an academic lab published some preclinical data on a potentially repurposable molecules, nothing can be done anymore? or could more in-depth preclinical validation be considered as « novel-enough »?
Saif Sikdar
53:22
if I find a compound (X) which has good efficacy alone, but one company patented another compound (Y) and showed an example of using Y with a conjugate of our compound like Y-X, can we still patent it, X?
Darren Derksen
53:32
If you have a discovery based on a re-purposed compound as well as novel compounds that work against the same target but have better properties (in terms of potency, solubility etc), do you have suggestions for the best way to pursue patent protection?
Bayrock
58:02
CAn changing excipient ratios in a formulation classify as novel?
Megha Bajaj
01:08:56
Sorry I will try to speak up more
Morgan Guo
01:10:23
thank you!
Griselda
01:10:23
Thank you very much! excellent presentation!
Darren Derksen
01:10:24
Very helpful, thank you!
Ron
01:10:25
Thanks! Very insightful
William Szczepaniak
01:10:27
Thank you!
Giselle
01:10:44
Thank you